JPWO2022149050A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022149050A5 JPWO2022149050A5 JP2023541864A JP2023541864A JPWO2022149050A5 JP WO2022149050 A5 JPWO2022149050 A5 JP WO2022149050A5 JP 2023541864 A JP2023541864 A JP 2023541864A JP 2023541864 A JP2023541864 A JP 2023541864A JP WO2022149050 A5 JPWO2022149050 A5 JP WO2022149050A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- epitope binding
- cancer
- bispecific
- dual specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014914 Carrier Proteins Human genes 0.000 claims 41
- 108091008324 binding proteins Proteins 0.000 claims 41
- 230000009977 dual effect Effects 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 10
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135812P | 2021-01-11 | 2021-01-11 | |
| US63/135,812 | 2021-01-11 | ||
| PCT/IB2022/000009 WO2022149050A2 (en) | 2021-01-11 | 2022-01-11 | Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502371A JP2024502371A (ja) | 2024-01-18 |
| JP2024502371A5 JP2024502371A5 (https=) | 2025-01-23 |
| JPWO2022149050A5 true JPWO2022149050A5 (https=) | 2025-01-23 |
Family
ID=82357225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541864A Pending JP2024502371A (ja) | 2021-01-11 | 2022-01-11 | 抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12331116B2 (https=) |
| EP (1) | EP4274852A4 (https=) |
| JP (1) | JP2024502371A (https=) |
| KR (2) | KR102618718B1 (https=) |
| CN (1) | CN117321079A (https=) |
| WO (1) | WO2022149050A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| USD1094401S1 (en) * | 2023-02-20 | 2025-09-23 | Sony Interactive Entertainment Inc. | Display screen or portion thereof with transitional graphical user interface |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102178323B1 (ko) * | 2013-11-29 | 2020-11-13 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| EP3686219A1 (en) * | 2014-02-04 | 2020-07-29 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| KR102259232B1 (ko) * | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| WO2017019846A1 (en) * | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| WO2017123548A1 (en) * | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| BR112019013189A2 (pt) * | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| US20210340250A1 (en) * | 2017-05-30 | 2021-11-04 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| WO2019089753A2 (en) * | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| KR20240017090A (ko) * | 2018-03-23 | 2024-02-06 | 일라이 릴리 앤드 캄파니 | 항-pd-1 항체와의 조합을 위한 항-cd137 항체 |
| US12065476B2 (en) * | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| EP3823988A1 (en) * | 2018-07-19 | 2021-05-26 | Eli Lilly and Company | Bispecific antibodies targeting immune checkpoints |
| WO2020047319A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
| NZ774126A (en) * | 2018-09-14 | 2023-05-26 | Akso Biopharmaceutical Inc | Spd-1 variant - fc fusion proteins |
| WO2020068500A1 (en) * | 2018-09-26 | 2020-04-02 | Albert Einstein College Of Medicine | Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof |
| GB201817822D0 (en) * | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| CN113840835B (zh) * | 2019-05-15 | 2024-06-25 | 克雷森多生物制剂有限公司 | 结合分子 |
| WO2021007428A2 (en) * | 2019-07-09 | 2021-01-14 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
-
2022
- 2022-01-11 EP EP22736677.0A patent/EP4274852A4/en active Pending
- 2022-01-11 JP JP2023541864A patent/JP2024502371A/ja active Pending
- 2022-01-11 CN CN202280009724.5A patent/CN117321079A/zh active Pending
- 2022-01-11 KR KR1020227040417A patent/KR102618718B1/ko active Active
- 2022-01-11 WO PCT/IB2022/000009 patent/WO2022149050A2/en not_active Ceased
- 2022-01-11 KR KR1020237005801A patent/KR102576861B1/ko active Active
- 2022-01-11 US US17/647,665 patent/US12331116B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| Lu et al. | Di-diabody: a novel tetravalent bispecific antibody molecule by design | |
| Deyev et al. | Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design | |
| JP2022065174A5 (https=) | ||
| JP2022064924A5 (https=) | ||
| Zuo et al. | An efficient route to the production of an IgG-like bispecific antibody | |
| US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| JP2022031784A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| CA3033694C (en) | Antigen binding protein against her3 | |
| JP2020114210A5 (https=) | ||
| RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2021515798A5 (https=) | ||
| JP2014113150A5 (https=) | ||
| JPWO2019234220A5 (https=) | ||
| JP2022009816A5 (https=) | ||
| JP2021525537A5 (https=) | ||
| JPWO2022133169A5 (https=) | ||
| JPWO2020011976A5 (https=) | ||
| JPWO2019191120A5 (https=) | ||
| JP2021508468A (ja) | メディトープ対応ｔ細胞 | |
| JPWO2022094299A5 (https=) | ||
| Yu et al. | Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds | |
| JPWO2022149050A5 (https=) |